Skip to content

Efficacy of Transcranial Magnetic Stimualtion in relieving symtooms in Parkinsons Disease.

Repetetive transcranial magnetic stimulation in Parkinsons disease - rTMS in PD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/01/011563
Enrollment
20
Registered
2018-01-25
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Parkinsons Disease Health Condition 2: G20- Parkinsons disease

Interventions

Sponsors

All India Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Diagnosis of clinically definite PD, defined by UKPD brain bank clinical and diagnostic criteria. With presence of at least 1 out of 3 cardinal motor features of PD (resting tremor, rigidity, and postural impairment like bradykinesia); 2. PD patients of both gender with H&Y stage from 1 to 2. 3. PD patients between age 45 to 75 on stable medication for at least 30 days

Exclusion criteria

Exclusion criteria: 1. Features suggestive of other causes of Parkinsonism/ Parkinson-plus syndromes; 2. History of surgery on brain for any indication, significant headaches, epilepsy or seizure disorder, mass lesions, or major head trauma leading to loss of consciousness of any length; 3. Family (1st degree relatives) history of epilepsy; 4. History of schizophrenia, schizoaffective disorder, other psychosis, claustrophobia; rapid-cycling bipolar illness, alcohol/drug abuse within the past year; 5. Need for rapid clinical response due to conditions such as psychosis, or suicide tendency; 6. Patients with uncontrolled hypertension and diabetes and other uncontrolled medical illness. Patients with hypertension or diabetes would be included only if they are stable on medication for last six months.

Design outcomes

Primary

MeasureTime frame
i. To compare the status of cortical plasticity between two treatment groups (M1, SMA) using FDG-PET. Timepoint: Baseline 0 day Post Sham at 4th week Post Real at 8th week [Baseline:-After recruitment Post-Sham:-After 4 sessions of Sham TMS Post-Real:- After 4 sessions of Real TMS.]

Secondary

MeasureTime frame
To compare the clinical condition of the patients in the two treatment groups on the basis of UPDRS. Timepoint: Baseline 0 day Post Sham at 4th week Post Real at 8th week [Baseline:-After recruitment Post-Sham:-After 4 sessions of Sham TMS Post-Real:- After 4 sessions of Real TMS.]

Countries

India

Contacts

Public ContactVinay Goyal

All India Institute of Medical Sciences

drvinaygoyal@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026